OSU6162 as a potential novel drug treatment for Parkinson's disease: effects on dopamine D2 receptor binding in human brain studied using PET.
Completed
- Conditions
- Parkinsons disease10028037
- Registration Number
- NL-OMON36314
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 12
Inclusion Criteria
Investigational group:
healthy volunteers (males)
Age between 50-60 years
Good physical health evaluated by medical history, physical (including neurological) examination RDC (Research Diagnostic Criteria) diagnosis never mentally ill
Exclusion Criteria
Exclusion criteria include a history of a neurological or psychiatric disorder, the use of any centrally active medication, drug abuse (a toxicology screening of urine will be performed to detect opiates, cocaine, amphetamines, cannabis, methadone, benzodiazepines and barbiturates), and participation in other studies involving radiation exposure.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Striatal binding potential (BPND) values will be used as outcome measure.<br /><br>Striatal D2 receptor occupancy (%) will be calculated according to: occupancy =<br /><br>100 * (1 * BPOSU/BPbaseline).</p><br>
- Secondary Outcome Measures
Name Time Method <p>nvt</p><br>